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Abstract 
 
Background: Recommendations for screening for Type 2 Diabetes Mellitus (T2DM) are based 
on evidence containing large amounts of uncertainty regarding the relative benefits and harms of 
screening. Evidence is particularly scarce about the potential psychological harms.   
Objective: This systematic review examines the literature to determine what is currently known 
about the psychological harms of screening for T2DM. 
Methods: PubMed, EMBASE, PsycINFO, and reference lists of published literature were 
searched for English-language studies published up until April 5
th
, 2013. Studies assessing 
psychological outcomes for at least one screened group within 3 years of screening were 
included. Data from included studies were extracted and strength of evidence was assessed for 
each psychological outcome.  
Results: Out of 4,435 search results, 14 articles were included. Screening produces a dose-
dependent effect on levels of anxiety and worry shortly after testing. A diagnosis of screen-
detected diabetes is associated with higher cognitive distress as well as thought intrusiveness. 
Depression appears to be associated with treatment of screen-detected diabetes, but not the actual 
screening test or diagnosis itself. Screening appears to have no effect on general psychological 
quality of life or negative well-being. Overall strength of evidence is low due to the few number 
fair of studies assessing each outcome. 
Conclusion: Overall, the available literature is insufficient to say with high certainty that 
screening for T2DM results in meaningful psychological harm, though the included studies hint 
that screening is not entirely benign.   
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Introduction 
 At first glance, type 2 diabetes (T2DM) appears to represent a reasonable target for 
screening. It affects a large percentage of the population, with an estimated 25 million people, or 
8.3% of the U.S. population having diabetes.
1
 Of those 25 million people, 27% remain 
undiagnosed, largely because diabetes has an identifiable latent phase, meaning people often 
have blood sugar levels consistent with diabetes for years without displaying any signs or 
symptoms.
2,3
 Another 79 million people meet criteria for “pre-diabetes,” (also called impaired 
glucose tolerance and impaired fasting glucose) a term used to classify the people with blood 
glucose higher than the “normal” range but not high enough to meet the threshold for diabetes.1,3  
Additionally, valid and reliable tests can detect diabetes in asymptomatic individuals.
2
 Therefore, 
screening has the potential to identify a large number of people with asymptomatic T2DM, 
allowing for early detection and treatment to reduce negative health outcomes. 
 In addition to the above qualities, however, a screening program must demonstrate a net 
benefit large enough to justify its implementation.
4
  Unfortunately, evidence about potential 
benefits and harms of T2DM screening is scarce. For example, one of the most important 
screening tenets dictates that treating a disease early (in the asymptomatic phase) must produce a 
net morbidity and/or mortality benefit compared to treating only clinically-apparent disease.
4
 
Evidence up to this point looking at T2DM screening contains a large degree of uncertainty on 
this issue. 
Ideally, we would like a randomized controlled trial (RCT) that assesses the direct effect 
of screening for T2DM on health outcomes. Unfortunately, only one such study has been done. 
The ADDITION-Cambridge study was a cluster randomized screening trial that was nested 
2 
 
within a larger trial looking at intensive vs. usual treatment of screen-detected diabetes. After a 
10 year follow-up, the study found no difference in all-cause or cardiovascular-related mortality 
between screened and unscreened groups.
5
 Aside from this limited trial data, a 2008 systematic 
review performed for the U.S. Preventive Services Task Force (USPSTF) found mixed results 
about potential benefits from only a small collection of observational and modeling studies.
2
  
 Despite very low certainty about the benefits of screening thus far, many guideline 
development groups recommend some form of screening, generally among groups they deem to 
be higher risk for diabetes. Table 1 lists several such groups and their recommendations. Of the 
groups that report grades along with their guidelines, many indicate that they based these 
recommendations on moderate to low quality evidence, meaning that as new evidence emerges, 
these recommendations may change.  
Despite no definitive evidence of substantial benefit, these groups still recommend 
routine screening likely because there may be benefit for some people while there appears to be 
little demonstrable harm.
2,3
 The screening cascade generally contains multiple parts. First, 
patients undergo initial blood tests, which if positive, will likely result in a confirmatory test. If a 
person is diagnosed, then he or she may begin a variety of treatments aimed at lowering blood 
sugar. The person may or may not subsequently progress to symptomatic disease, which can, in 
turn, produce negative health outcomes in the future. At any point along this cascade, the 
possibility of harm exists. 
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Table 1. List of guideline development groups and their recommendations. Strengths of the 
recommendations (if applicable) are as stated by their respective group and may be different 
from those of other groups. 
Group Recommendations (Strength) 
American 
Diabetes 
Association
6
  
- Recommends screening adults of any age who are obese and have one or 
more of the following (B: supportive evidence from well-conducted 
cohort studies): 
- Physical inactivity 
- First degree relative with diabetes 
- High-risk ethnicity 
- Women with history of gestational diabetes or   delivered a baby 
weighing >9 lbs 
- Hypertension (BP 140/90) or on therapy  
- HDL <35 mg/dL and/or triglycerides >250 mg/dL 
- Women with polycystic ovarian syndrome 
- A1C >5.7%, IGT or IFG on previous testing 
- Other clinical conditions associated with insulin resistance (severe 
obesity, acanthosis nigricans) 
- History of cardiovascular disease 
- In the absence of these factors, screen beginning at 45 years (E: expert 
consensus) 
- If “prediabetes,” test yearly 
 
The Endocrine 
Society
7
 
- Recommends screening with fasting plasma glucose as part of screening 
for the components of metabolic syndrome. (strong recommendation: 
moderate quality evidence) 
- This should be done every 3 years (weak recommendation: very low 
quality evidence) 
- Recommends screening for type 2 diabetes every 1-2 years in people 
previously diagnosed with IFG or IGT (weak recommendation: very low 
quality evidence) 
American Heart 
Association
8
 
- Recommends screening in adults who are: 
- Overweight and over age 45 
- Overweight, under age 45 and one or more of the following 
- Hypertension 
- High cholesterol 
- Family history of diabetes 
- African-American, Asian-American, Latino, Native American or 
Pacific Islander 
- History of gestational diabetes or delivered a baby > 9 lbs 
- Recommends screening every 3 years if tests are normal 
- Recommends screening every 1-2 years if prediabetes 
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United States 
Preventive 
Services Task 
Force
9
 
- Recommends screening in adults with sustained blood pressure >135/80 
(B:high certainty that net benefit is moderate or there is moderate 
certainty that net benefit is moderate to substantial) 
National 
Institute for 
Health and Care 
Excellence
10
 
- Recommends screening for those with a high risk score on a validated 
risk-assessment tool or self-assessment questionnaire. 
- Recommends screening for those aged 25 and over of South Asian or 
Chinese origin who have a BMI > 23 kg/m
2
  
 
Canadian Task 
Force on 
Preventive 
Health Care
11
 
- Recommends screening adults at high risk of diabetes (33% chance of 
developing diabetes within 10 years as determined by validated risk 
score) every 3-5 years. (weak recommendation: low-quality evidence) 
- Recommends screening adults at very high risk (50%) annually (weak 
recommendation: low-quality evidence) 
- Recommends not screening those at low to moderate risk (1-17%) (weak 
recommendation: low-quality evidence) 
International 
Diabetes 
Federation
12
 
- Recommends screening those at “high risk.” No interval specified  
- Recommends identifying those at “high risk” using questionnaire to 
assess age, waist circumference, family history, cardiovascular history, 
and gestational history. 
 
In general, the potential harms of screening for T2DM can be divided into two categories: 
physical and psychological. Physical harms largely include possible consequences of treating 
screen-detected diabetes, such as hypoglycemia, cardiovascular outcomes, and more minor drug-
specific side effects.
2
 Psychological harms are broader, including effects from an invitation to 
screening, the actual screening test, false positives, false negatives, labeling, and distress related 
to disease management. Aside from the potential physical and psychological harms present 
throughout the cascade, the patient must also endure the hassle of spending time and money 
undergoing tests and receiving treatment.  
Unfortunately, evidence about the effects of screening on psychological outcomes is 
lacking, as diabetes-related studies tend to focus more on “harder” clinical outcomes.2,3,13  
Therefore, recommendations for T2DM screening actually incorporate incomplete harms 
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evidence, meaning that screening large numbers of individuals could, in fact, be causing harm. It 
is therefore important to understand what is currently known and unknown about the potential 
harms of screening for T2DM. The objective of this review is to systematically examine the 
current evidence for the harms of screening for T2DM. For the purposes of this review we will 
focus only on psychological harms. 
Methods 
This systematic review examines the evidence about the psychological harms of 
screening for T2DM. In this review, I defined screening as the testing of asymptomatic 
individuals to detect “abnormal” blood glucose levels. These tests include blood tests for 
Hemoglobin A1C (A1C), Fasting Plasma Glucose (FPG), and Oral Glucose Tolerance Test 
(OGTT).  
Although the screening cascade contains many facets, for simplicity I have divided the 
screening process into 2 phases: (1) the process of the actual screening test, subsequent work-up, 
and labeling of the patient; and (2) the process of treating the screen-detected patient.  Two Key 
Questions (KQs) correspond to these two phases:  
Key Question 1 (KQ1): What are the psychological harms of screening for T2DM? 
Key Question 2 (KQ2): What are the psychological harms of treating screen-detected 
T2DM? 
 
 
 
6 
 
Table 2: Eligibility Criteria for Included Studies 
 Inclusion 
Population Adults age >18 years who have one or more of the following: 
 
  -Undergone screening for abnormal blood glucose levels 
  -Screen-detected type 2 diabetes (non-insulin dependent 
diabetes)  
  usually defined as the combination of any two or more of the 
following
6
: 
       - Hemoglobin A1C ≥ 6.5% 
       - Fasting Plasma Glucose ≥ 126 mg/dL 
       - 2hr Plasma glucose ≥ 200 mg/dL during an OGTT 
  -Impaired glucose tolerance defined as 2hr plasma glucose 140-
200 mg/dL  
  -Impaired fasting glucose defined as fasting level of 100-125 
mg/dL  
  -Individuals with asymptomatic type 2 diabetes diagnosed <3 
years from measurement of outcome.  
 
Individuals must be previously undiagnosed with depression, 
anxiety, or other psychological disorder prior to screening 
 
Intervention Screening for type 2 diabetes, impaired glucose tolerance, or 
impaired fasting glucose using Hemoglobin A1C, Fasting Plasma 
Glucose, or Oral Glucose Tolerance Test 
Comparison Adults without screening or screen detected diabetes (including 
people who have undergone screening but have received a 
negative result) 
Outcomes Psychological outcomes during or after screening including: 
-Depression  
-Anxiety 
-Worry 
-Fear 
-Distress 
-Decrease in psychological quality of life 
Timeframe From first screening to 3 years after diagnosis of diabetes or 
IGT/IFG 
Time Period 1966-present 
Study Design -Randomized Controlled Trials 
-Cohort Studies 
-Case-Control Studies 
-Qualitative Studies 
-Systematic Reviews 
Study setting  Primary care clinics at the beginning of study 
 
7 
 
Eligibility Criteria 
I determined eligibility criteria in the form of PICOTTSS (Population, Intervention, 
Comparators, Outcomes, Timeframe of study, Time period of search, Study designs accepted, 
and Study setting accepted). Table 2 details all of the inclusion criteria. 
I included studies of adults 18 years and older, including both men and women, who 
underwent T2DM screening or have screen-detected T2DM or Impaired Fasting 
Glucose/Impaired Glucose Tolerance (IFG/IGT). I included only individuals without depression, 
anxiety or any other psychological disorders prior to screening, as I was interested only in the 
effect of screening on psychological well-being, not the incidence of T2DM in those with pre-
existing mood disorders. To answer KQ2, I included studies investigating psychological well-
being among those receiving treatment for screen-detected diabetes. As an indirect measure of 
screen-detected diabetes, I also included individuals with asymptomatic diabetes of 3 years 
duration or less. I excluded studies if the study did not explicitly identify one group as having 
screen-detected or asymptomatic T2DM within the specified time frame. For randomized 
controlled trials (RCTs), qualitative studies, cohort, and case-control studies, relevant 
comparators included those who have not undergone screening for T2DM, those who have 
clinically diagnosed T2DM i.e., received a diagnosis after displaying signs and symptoms, or 
those with a negative result from a screening test. 
I included any study investigating psychological outcomes related to screening including 
depression, anxiety, worry, fear, distress, diabetes-related distress, or change in psychological 
quality of life. I considered outcomes within 3 years of diagnosis, because those receiving 
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standard treatment for screen-detected diabetes may not experience distress until after the first 
year following diagnosis.
14
  
Search Strategy 
I searched PubMed
®
, Embase, and PsycINFO
®
 for all systematic reviews and studies 
published up until April 5, 2013. I chose to include English-language cohort, case-control and 
qualitative studies in addition to systematic reviews and randomized trials in anticipation that 
very few of the latter studies would be available on this topic. I also reviewed the reference lists 
of included studies for any other relevant citations.  
To develop the search strategy, I consulted a health sciences librarian, who assisted in the 
development of relevant search terms. For interventions, I used the Medical Subject Heading 
(MeSH term) “diabetes mellitus, type 2” as well as the key words “non insulin dependent 
diabetes,” “impaired fasting glucose” and “impaired glucose tolerance,” along with the MeSH 
terms “mass screening,” “hemoglobin A, glycosylated,” and “glucose tolerance test,” as well as 
key words such as “screen,” “early diagnosis,” “early detection,” and “fasting glucose.” Finally, 
for the outcomes we used key words such as “depression,” “distress,” “worry,” “fear,” “anxiety,” 
and “quality of life.” Of note, the term “diabetes-related distress” is a disease-specific outcome 
referring to psychological effects of carrying the diagnosis of and receiving treatment for 
diabetes.
15
 I did not include “diabetes-related distress” as a separate term, because I expected that 
the broader term “distress” would be sensitive enough to find any studies examining this 
diabetes-specific outcome. Due to differences among the databases’ index words, search terms 
were slightly different for each data source. The full search strategy is listed in Appendix A.  
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Data Management 
All titles and abstracts were imported into RefWorks 2.0 (ProQuest, LLC). I reviewed 
and compared the titles and abstracts against inclusion and exclusion criteria, excluding those 
that clearly did not meet the criteria. I then reviewed the remaining full-text articles to determine 
which studies would ultimately be included. Due to limited resources a dual-review was not 
performed; however in the event of a dual-review, if either reviewer considered a result eligible, 
it would be included for full-text review. Then, the independent reviewers would review the full-
text articles, and if a subsequent consensus was not reached, a third, senior reviewer would 
resolve disagreements about inclusion. 
Data from included studies was then abstracted into evidence tables. These data include 
study type, participant information, intervention, comparators, outcome assessment, and results. 
Here again, a dual-review was not feasible, but would have included a second reviewer checking 
data tables for consistency. Disagreements would have been settled by discussion and consensus.  
Strength of Evidence 
 I adapted criteria from the United States Preventive Services Task Force (USPSTF) and 
the Evidence-based Practice Center program of the Agency for Healthcare Research and Quality 
to rate strength of evidence.
16,17
  
I first rated the internal and external validity of each individual study. Internal validity 
refers to the risk of bias in each study, while external validity refers to what degree the study 
results can be generalized to other populations. Risk of bias for each individual study was 
evaluated according to USPSTF criteria for internal validity.
16
 These criteria include creation and 
preservation of comparable groups, high degree of follow-up, measurement of intervention and 
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outcomes, and appropriate analysis that addresses and corrects for potential confounders, 
including an intention to treat analysis for RCTs. Based on these criteria, each study received a 
rating of good, fair, or poor. Good studies met all of the listed criteria and had the least risk for 
bias. Fair studies generally met all criteria without any major flaws, though still were susceptible 
to some bias. Poor studies had at least one major flaw such as non-comparable study groups, 
severe attrition rates, or inattention to key confounders. Poor studies were excluded from further 
review.  
I evaluated the generalizability for each study using the USPSTF criteria for external 
validity.
16
 These criteria call for examining each study’s population, situation, and providers, 
each of which may contain characteristics limiting the results’ generalizability. For example, a 
study population may include or exclude certain ages, genders, ethnicities, comorbidities, or 
income levels that affect the outcomes of interest. The study situation is the degree to which the 
environment or context would likely be replicated, for instance whether the intervention of 
interest is as readily available among general practice as it is in the study. Finally, the providers 
in the study may have different training or skills than the majority of providers nationwide. 
Depending on the degree of generalizability, each study received a rating of good, fair, or poor. 
Good studies differed slightly from general population, situation, and providers such that the 
study results still had a high likelihood of occurring in usual practice. Fair studies contained 
differences that moderately affected likelihood of attaining results in general practice, while poor 
studies contained substantial differences with low likelihood of applying to general practice. I 
did not exclude studies with poor generalizability, as they could still have internally valid results 
that apply to a specific population or setting.  
11 
 
Next I rated aggregate internal and external validity of the studies for each outcome. 
Aggregate validity not only synthesizes individual study validities; it also addresses the strength 
of each study design and whether the study designs were sufficient to answer the question. I gave 
a rating of high, moderate, or low for both overall internal and external validity. 
I also rated the consistency of evidence for each outcome. Consistency refers to the 
degree to which the evidence shows a uniform direction and magnitude of effect.
17
 For my 
results, a study could show strongly positive, mildly positive, negative, or no difference in 
psychological outcomes. Generally evidence is considered inconsistent if results contain both 
large positive and negative effects; however I also considered results inconsistent if they showed 
any degree of no difference in addition to large positive or negative effects. If multiple studies 
were included for a key question, I gave a rating of either “consistent” or “inconsistent.” If there 
was only one study for a given key question, I gave a rating of “not applicable.”17 
Finally, I rated precision for each outcome. Precision is the statistical and conceptual 
certainty of an intervention’s effects.16,17 Statistical certainty includes the confidence interval 
around a point estimate. Conceptual certainty considers the number and size of the studies that 
form the evidence base. I gave ratings of “high,” “moderate,” or “low,” along with justifications 
for each rating. Evidence with high precision had an adequate number of well-performed large 
studies that showed consistent results. Moderately precise evidence may have some degree of 
uncertainty due to small inconsistencies, fewer studies, or small faults in study quality. Evidence 
with low precision suffers from limitations such that one cannot draw conclusions due to large 
statistical uncertainty, very few studies or markedly inconsistent results. Evidence with moderate 
or low precision is likely to change in magnitude and/or certainty with the development of new 
evidence.  
12 
 
Data Synthesis 
 I qualitatively synthesized data to answer each key question using their outcomes and 
strength of evidence. Then, using the evidence from each key question, I drew an overall 
conclusion about the psychological harms associated with screening for type 2 diabetes. I did not 
perform a meta-analysis due to significant heterogeneity in outcomes. 
Results 
 I identified a total of 14 articles related to 8 studies for inclusion. An electronic search of 
PubMed
®
, Embase, and PsycINFO
®
, produced a total of 4,429 results, and a review of references 
produced another 6 results. After a removal of duplicates, 3,936 results remained. I excluded 
3,866 results after a title and abstract review, leaving 70 articles for full-text review. Of these 70, 
56 articles were excluded, the majority for wrong publication type; see flow diagram Figure 1. 
Many of the other studies excluded during full-text review did not have appropriate comparison 
groups or did not specify that diabetes was screen-detected.  
Characteristics of Included Studies 
Fourteen results remained for inclusion:  11 prospective cohort studies, 1 prospective qualitative 
study, 1 randomized controlled trial, and 1 non-randomized controlled trial.  The sample sizes 
ranged from 23 to 7,380 for a total of 19,860 participants, and the mean age of the participants 
ranged from 55-68 years. Study duration ranged from 6 weeks to 13 years. Eight studies took 
place in the U.K., 3 in The Netherlands, 2 in the U.S., and 1 in Germany. Individual study 
characteristics can be found in Appendix B. 
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Figure 1. Flow diagram of included studies (Adapted from the PRISMA statement
18
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All included studies had at least 1 group that underwent screening for diabetes. Three 
studies compared screened and unscreened groups;
19-21
 two compared outcomes between people 
with screen-detected diabetes and people with diabetes detected in general practice;
22,23
 six 
studies compared those who screened positive with those who screened negative for T2DM;
24-29
 
and two assessed outcomes between groups undergoing screening several years apart.
30,31
 
Finally, the qualitative study investigated the experiences of people undergoing a stepwise 
screening process.
32
 
Most studies employed targeted screening on “high-risk” populations. Those associated 
with the ADDITION trial, a randomized trial in which primary care clinics were cluster 
randomized to screening or no screening, identified individuals using a risk factor 
questionnaire.
19-21,29,32
 Studies associated with the Hoorn Screening Study, a targeted screening 
project carried out in a Dutch population, used a similar diabetes symptom and risk 
questionnaire.
22,24,25
 One study screened siblings of people with T2DM.
27
 Five studies did not 
specifically target higher risk individuals; however two of these drew study populations from 
larger studies investigating correlates of cardiovascular disease.
23,28
  
The most commonly assessed outcome was general mental health(five studies),
22,24,26,30,31
 
followed by anxiety (four studies)
20,21,27,29
 and depression(four studies).
21,23,28,29
 Three studies 
reported changes in negative well-being,
22,24,25
 and two of these also measured cognitive 
distress.
22,25
 Worry,
21
 false reassurance,
19
 and frequency of thought about what it would be like 
to have diabetes
27
 were each measured once. The tools used to measure the various 
psychological outcomes are listed in Table 3. 
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Table 3. Characteristics of Psychological Outcomes Assessment Tools 
Outcome Assessment Tool Description 
Mental Health Medical Outcomes Survey 
Short Form 36 item (SF-36) 
A generic quality of life measurement tool 
with a physical subscale and a mental 
subscale
33
 
 
Higher scores indicate better quality of life 
Anxiety 1. Spielberger State Anxiety 
Inventory Short Form (SSAI-
SF) 
 
2. Hospital Anxiety and 
Depression Scale-Anxiety 
(HADS-A) 
1. A generic measurement tool that 
assesses state of short-term anxiety
34
  
>40  indicates clinically significant 
anxiety 
 
2. A generic measurement tool that 
assesses generalized anxiety 
0-7           No anxiety 
8-10         Mild anxiety 
11-14       Moderate anxiety 
15-21       Severe anxiety 
Negative Well-
Being  
 
“Negative mood”25 
Negative Well Being 
Subscale of Dutch Short 
Version of the Well-Being 
Questionnaire (WBQ-12) 
Generic quality of life measurement tool 
that assesses depression and anxiety 
>4  indicates elevated depressive 
symptomatology 
Depression 1.Hospital Anxiety and 
Depression Scale-Depression 
(HADS-D) 
 
2.Center for Epidemiologic 
Studies Depression Scale 
(CES-D) 
1. Generic measurement tool that assesses 
depressive symptoms.
35
 
0-7         No depression 
8-10       Mild 
11-15     Moderate 
>15        Severe 
 
2. Generic measurement tool assessing 
current level of depressive symptoms 
>16   indicates  clinical depression 
 
Cognitive Distress Diabetes Symptom Checklist A diabetes-specific checklist assessing 
occurrence of symptoms over eight 
domains, one of which is cognitive 
distress
25
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Outcome Assessment Tool Description 
False Reassurance 2 questions asked to patients 
to indicate: 
1. Perceived risk 
2. Comparative risk 
 
(non-validated measure) 
1. Perceived risk: chance of getting 
diabetes in the future; expressed as a 
percentage 0-100% on 11-point scale
19
 
 
2. Comparative risk: chance of getting 
diabetes compared to other people of their 
own age; 1: much lower to 5: much higher 
 
Worry 6 item worry scale  
(non-validated measure) 
Assesses worry about developing diabetes 
in the future. Adapted from Lerman 
cancer worry scale
21,36
 
Measures of 
Cognition 
(knowledge and 
beliefs) 
3 questions that elicit 
thoughts about diabetes  
 
(non-validated measure) 
1. Perceived risk: likelihood of developing 
diabetes; expressed as Likert scale “very 
likely” to “not at all likely”27 
 
2. Occupied thoughts: how much the 
person thinks about what it would be like 
to have diabetes; “never” to “all the time” 
 
3.  Thoughts on complications: likelihood 
of developing complications if diagnosed 
with diabetes; “very unlikely” to “very 
likely” 
Most of the tools used to measure psychological outcomes were generic tools that are 
generally used for people with various conditions. Only four of the ten tools were specific to 
diabetes: the Diabetes Symptom Checklist, and the study-specific questions assessing false 
reassurance, worry, and knowledge and beliefs about diabetes. Out of those four, only one, the 
Diabetes Symptom Checklist, appeared to be used and validated in other studies.
22,24,25
   
Key Question 1 (KQ1): What are the psychological harms of screening for T2DM? 
Mental Health 
Five studies measured mental health; none of these compared screened and unscreened 
populations. Compared to people with diabetes detected in general clinical practice, those with 
17 
 
screen-detected diabetes had significantly better SF-36 Mental Health Component (MHC) scores 
from 2 weeks to 1 year of follow-up (mean scores at 1 year 54.3 vs. 50.8; p=0.009).
22
 However, 
when adjusted for multiple comparisons, this difference is no longer significant. Among people 
screened for diabetes, there was no significant difference in scores at 1 year between those who 
screened positive and those who screened negative.
24,26
 Additionally, among those screened, 
there was no difference in mental health scores between people 1-3 years after screening and 
people 10-13 years after screening.
30,31
 
Anxiety 
 Four studies measured anxiety, two of which were trials comparing screened and 
unscreened groups. In one, screened individuals had similar scores on SSAI and HADS-A as 
unscreened individuals at the time of screening and at 3-6 and 12-15 months.
21
 Neither of the 
groups had mean scores suggesting clinically important anxiety at any time. In contrast, the 
second trial showed that those invited for screening had significantly higher mean anxiety scores 
at 6 weeks than those not screened (37.6 vs. 34.1, respectively; p=0.015); although, neither of 
these scores represents clinically important anxiety.
20
 Of note, a subgroup analysis indicated an 
increasing trend in anxiety scores corresponding with progression through the step-wise 
screening process, with a significant difference between those ultimately diagnosed with diabetes 
and those testing negative at initial screening. Furthermore, the mean anxiety score among those 
diagnosed indicated clinically important anxiety.
20
  
In a screening study of siblings of people with diabetes, there was no difference in 
anxiety scores between those testing positive and those testing negative at 1 year follow-up.
27
 
However, both groups had significantly lower scores at 1 year compared to “baseline” values 
18 
 
right before screening. A similar study showed no difference in the percentage of people meeting 
criteria for anxiety at 1 year between those with positive test results and those with negative test 
results.
29
 
Depression 
 Four studies assessed depressive symptoms; only one of these studies compared screened 
and unscreened groups. In this trial, there was no difference in HADS Depression scores between 
the screened and unscreened groups at 3 and 12 months after screening.
21
 Studies comparing 
screen-positive and screen-negative groups showed no difference in depression scores at 1 
year.
27,29
 One study compared a group with screening-confirmed normoglycemia to a group with 
impaired fasting glucose and one with untreated diabetes.
28
 Neither of the latter groups had an 
increased odds of depressive symptoms over 5 years compared to the normoglycemic group. 
Negative Well-being 
 Three related studies measured negative well-being, which they equated to negative 
mood. Compared to people with diabetes newly detected in clinical practice, those with screen-
detected diabetes had similar scores on the Negative Well Being subscale of the Well-Being 
Questionnaire.
22
 There was also no difference between individuals with screen-detected diabetes 
and those that screened negative.
22,24,25
 
Cognitive Distress 
 Two of the three studies that measured negative well-being also assessed cognitive 
distress as one domain in an array of diabetes symptoms; however only one of the studies 
19 
 
compared differences between groups;
25
 the other assessed for change in distress over time 
within groups.
22
 In the latter study, people with diabetes detected in general practice had 
significantly lower distress at 1 year as compared to 2 weeks after diagnosis, whereas those with 
screen-detected diabetes did not change significantly over the same period.
22
 At 1 year, the two 
groups appeared to have similar levels of distress. The second study showed that, compared to 
people who screened negative for diabetes, a significantly higher percentage of those with 
screen-detected diabetes had cognitive distress at 2 weeks and 6 months (2 weeks: 64% vs. 49%, 
p=0.043; 6 months: 64% vs. 45%, p=0.004).
25
 At 12 months, 60% of individuals with screen-
detected T2DM had reported symptoms of cognitive distress, compared to 52% of those who 
screened negative; however this difference was no longer significant. 
False Reassurance  
 One study assessed false reassurance between people who screened negative for diabetes 
and those who were unscreened.
19
 False reassurance refers to the idea that after receiving 
screening test results indicating no disease, a person will mistakenly underestimate their future 
risk of developing the disease.
19
 Compared to unscreened individuals, those receiving a negative 
screening test estimated a similar chance of developing diabetes in the future. However, 
immediately after screening those with a negative screening test rated their comparative risk 
significantly lower than did unscreened individuals. In other words, those who screened negative 
for T2DM were slightly more likely to say that, compared to other people their age, their future 
risk of developing diabetes was lower. This difference between groups was no longer significant 
at 6 months and 1 year.  
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Worry 
 One study assessed worry about developing diabetes in the future. People who underwent 
screening for diabetes expressed similar worry as did unscreened controls.
21
 However, among 
those screened, people with a positive result at the initial random blood glucose test showed 
significantly higher worry about developing diabetes in the future than did those with a negative 
result (8.18 vs. 7.97, p=0.002). Additionally, people further along in the screening process had 
significantly higher worry than did those for whom diabetes was ruled out early on in the 
process. For example, participants that progressed to an oral glucose tolerance test had 
significantly greater worry about developing diabetes than did those who initially screened 
negative at the random blood glucose test. Despite these differences between groups, a 
qualitative study suggested that overall worry remained low, possibly because patients regard 
initial screening tests as routine and generally expect negative results.
32
 Then, when testing 
positive early in the screening process, patients downplay the importance of the result, attributing 
it to a recent meal or normal fluctuation. Even when ultimately diagnosed with diabetes, most 
participants did not express much worry. 
Measures of Cognition 
 One study assessed the degree to which diabetes occupied participants’ thoughts.27 
Compared to those with normoglycemia, people whom screening identified as “at risk,” were 
significantly more likely to think about what it would be like to have diabetes (24.2% vs. 13.1%, 
p=0.006). They were also significantly more likely to think that developing diabetes was “quite 
or very likely” (58.2% vs. 31.5%, p=0.006). However, those deemed “at risk” were no more 
likely to expect complications in the event of developing diabetes. 
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Key Question 2: What are the psychological harms of treating screen-detected T2DM?  
There were no studies specifically looking at whether treating screen-detected T2DM 
produced psychological harms compared to delaying treatment until clinical detection. However, 
one study compared the development of depressive symptoms among various screened groups 
stratified by blood glucose levels.
28
 Although impaired fasting glucose and untreated diabetes 
were not associated with depression, people undergoing treatment for screen-detected diabetes 
had greater odds of having depressive symptoms at 5 years than did those with normal blood 
sugar (OR 1.52, 95% CI 1.09-2.12). 
Synthesis 
 Due to high levels of heterogeneity in outcomes, follow-up, and study design, the results 
were qualitatively synthesized. Results for the strength of evidence for each outcome are shown 
in Table 4. In general, strength of evidence for each outcome was low, due to the low number of 
corresponding studies.  Additionally, all of the studies were of fair quality, as significant loss to 
follow-up was a common problem. Other problems included failure to account for both baseline 
differences and missing data in the final analysis. The factors limiting external validity included 
the participant demographics and the screening process itself. For example, many of the studies 
comprised participants who were at a higher risk than the average screened individual for having 
undiagnosed diabetes.  Additionally, a considerable number of studies used a screening process 
that had more steps than would the U.S. general practice. For example, participants in the 
ADDITION trial underwent random glucose, fasting glucose, and oral glucose tolerance tests 
(progression to a subsequent test depended on prior positive results).
21
 Conversely, general 
diabetes screening the U.S. general practice usually involves 1-2 tests.
6
 Such a difference could 
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influence participants’ attitudes toward testing and subsequent diagnosis.  Full ratings for 
internal and external validity are included in Appendix C and Appendix D, respectively.  
Discussion 
The purpose of this systematic review was to assess the evidence on the psychological 
harms of screening for type 2 diabetes.  The considerable heterogeneity in comparison groups, 
outcomes, and results, as well as the overall low strength of evidence as assessed in this review, 
suggests that the evidence is currently insufficient to say with high certainty that screening for 
T2DM results in meaningful psychological harm.  
Two studies suggest that general psychological well-being remains unaffected among 
screened individuals, both those with positive and negative results. Additionally, those diagnosed 
clinically have slightly lower psychological quality of life than those who are screen-detected.
22
 
However, the strength of evidence for the relationship between psychological well-being and 
screening is low. 
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Table 4. Strength of Evidence for all outcomes stratified by comparison groups. 
Number of 
studies; # of 
participants  
Design(s)/Overall 
Internal Validity 
(reason) 
Overall External 
Validity 
Consistency Precision Strength of 
Evidence 
KQ1 
Mental Health: Screen-detected vs. General Clinical Practice 
1; 165 Prospective Cohort/ 
Fair: (high attrition 
rates; baseline 
dissimilarities not 
addressed in 
analysis)  
Fair: (Primarily 
Caucasian, 
identified 
through 
symptom 
questionnaire, 
stepwise 
screening 
process) 
N/A Precise Low 
Mental Health: Screen Positive vs. Screen Negative 
2; 1,512 Prospective Cohort/ 
Fair (Baseline 
characteristics 
different/unclear 
and not addressed in 
analysis) 
Fair to Good: 
(Primarily 
Caucasian, 
identified 
through 
symptom 
questionnaire, 
one study had a 
stepwise 
screening 
process) 
Consistent Imprecise Low 
 
 
 
 
 
Mental Health: 1-3 years post screening vs. 10-13 years post screening 
2; 1,593 Prospective Cohort/ 
Fair (high attrition 
rates) 
Fair: (Primarily 
Caucasian, 
relatively 
healthy 
population) 
Consistent Imprecise Low 
 
 
Anxiety: Screened vs. Unscreened 
2; 7,735 RCTs/ Fair (high 
attrition rates) 
Fair: (Study 
population very 
high risk, maybe 
more so than 
average 
screening 
population) 
Inconsistent Imprecise Low 
Anxiety: Screen Positive vs. Screen Negative 
2; 3,671 Prospective 
Cohorts/ Fair: (High 
attrition rates, 
unadjusted analysis) 
Fair: (Primarily 
Caucasian; step-
wise screening 
process) 
Consistent  Precise Low 
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Depression: Screened vs. Unscreened 
1; 7380 RCT/ Fair: (High 
attrition rate) 
Fair: 
(Participants 
higher risk than 
average 
screened 
population; 
Step-wise 
screening 
process) 
 
N/A Imprecise Low 
Depression: Screen Positive vs. Screen Negative 
3; 11,046 Prospective Cohort/ 
Fair to good: (One 
had high attrition, 
two had unclear 
discussion of 
masking) 
Fair to good 
(one study likely 
had higher risk 
than the average 
screened 
population) 
 
Consistent  Imprecise Moderate 
Negative Well-Being: Screen-detected vs. General Clinical Practice 
1; 165 Prospective Cohort/ 
Fair: (High attrition 
rates) 
Fair: (Primarily 
Caucasian, 
Participants 
likely higher 
risk than 
average 
screened 
population; step-
wise screening 
process) 
 
N/A Precise Low 
Negative Well-Being: Screened Positive vs. Screened Negative 
2; 319 Prospective Cohort/ 
Fair (High attrition) 
Fair: (Primarily 
Caucasian, 
Participants 
likely higher 
risk than 
average 
screened 
population; step-
wise screening 
process) 
Consistent Imprecise Low 
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Cognitive Distress: Screen-detected vs. General Clinical Practice 
1; 165 Prospective Cohort/ 
Fair: (High attrition) 
Fair: (Primarily 
Caucasian, 
Participants 
likely higher 
risk than 
average 
screened 
population; step-
wise screening 
process) 
N/A Imprecise Low 
Cognitive Distress: Screened Positive vs. Screened Negative 
1; 319 Prospective Cohort/ 
Fair: (High attrition 
rates) 
Fair: (Primarily 
Caucasian, 
Participants 
likely higher 
risk than 
average 
screened 
population; step-
wise screening 
process) 
N/A Precise Low 
Worry: Screened vs. Unscreened 
1; 7380 RCT/ Fair: (High 
attrition rate) 
Fair: 
(Participants 
likely higher 
risk than 
average 
screened 
population; 
Step-wise 
screening 
process) 
N/A Imprecise Low 
False Reassurance: Screened vs. Unscreened 
1; 5334 Prospective Cohort/ 
Fair: (High attrition 
rate) 
Fair: 
(Participants 
likely higher 
risk than 
average 
screened 
population; 
Step-wise 
screening 
process) 
N/A Imprecise Low 
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Measures of Cognition 
1; 431 Prospective Cohort/ 
Fair (Baseline 
differences not 
addressed in 
analysis) 
Fair to good 
(primarily 
Caucasian, were 
identified 
through siblings 
with T2DM, 
which is 
unusual) 
N/A Precise Low 
KQ 2: Depression 
1; 3285 Prospective 
Cohort/Fair to good 
(unclear discussion 
of masking, missing 
data not addressed) 
Good N/A Precise Low 
 
 
 The evidence suggested that screening produces a significant increase in short-term 
anxiety up to 6 weeks later compared to no screening; however this anxiety does not persist at 3 
months to 1 year after screening. Additionally, those who screen positive appear to experience 
higher anxiety immediately after diagnosis than those who screen negative, but again this 
difference is not present at 1 year. Interestingly, one cohort study showed that both people who 
screened positive and those who screened negative had lower anxiety scores at 1 year than before 
testing, indicating that perhaps the anticipation of screening initially made participants anxious.
27
 
This finding must be interpreted with caution, however, because it does not indicate whether 
anxiety measured prior to screening is anticipatory or reflects the participants’ usual, baseline 
levels. The screening process also appeared to have a dose-response effect on anxiety, with those 
progressing further reporting higher, clinically-significant levels. Therefore, available evidence 
suggests that both the screening process itself as well as a subsequent diagnosis both result in 
temporary anxiety.  
27 
 
The short-term nature of anxiety found in this review fits with a previous systematic 
review, which showed that upon receiving a result that predicts higher risk of illness, anxiety, 
along with depression and distress, rose for only the first 4 weeks.
37
  Although the strength of 
evidence is low for this outcome, the apparent dose-response relationship further supports the 
possibility that screening contributes to higher anxiety.  
One trial showed that depression levels were similar between screened and unscreened 
groups. Additionally, 3 cohort studies showed no difference in depressive symptoms and 2 
studies showed no difference in negative mood between those with screen-detected blood 
glucose abnormalities and those who screen negative. However, individuals with screen-detected 
diabetes who subsequently received treatment had higher odds of depression compared to those 
who screened negative. Although the latter comparison does not directly approximate the effects 
of treating screen-detected diabetes, it does support previous hypotheses suggesting that 
depression may be more related to treatment and its intensiveness than to the diagnosis of 
diabetes itself.
14,23,38
  This is also important because only two of the four studies assessing 
depression reported how many patients with diabetes were taking medications; one reported low 
rates of medication usage, and the other reported the above association between treated T2DM 
and depression.
23,28
 If the degree of diabetes management predicts incident depressive symptoms, 
a relatively low percentage of treatment among participants with screen-detected diabetes could 
explain a lack of difference in outcomes between these individuals and those who screened 
negative. Therefore, due to insufficient information about treatment, the available evidence in 
this review is insufficient to determine the full effect of the diabetes screening cascade on 
depression.  
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 More people who screen positive for T2DM experience cognitive distress for up to 6 
months following diagnosis than do those who screen negative. Screen-detected individuals also 
appear to have less distress at 2 weeks than those who are clinically detected; however this 
difference is very small and disappears at 6-12 months. Of note, these studies considered 
cognitive distress a symptom of diabetes; however it is not possible from the study design to 
determine whether this distress results from physiologic changes, the diagnosis, or the treatment 
of diabetes.  
Diabetes-specific worry appears not to be increased in screened vs. unscreened 
individuals; however those with screen-detected diabetes have greater worry compared to those 
who screen negative. Therefore, the lack of difference between screened and unscreened groups 
may be due in part to the fact that a large number of screened people had negative results. 
Additionally, those progressing further through the screening process had greatest worry. As 
with anxiety, this apparent dose-response relationship suggests that screening for diabetes does 
increase worry, though this effect may be limited to those who screen positive. However, even 
among individuals receiving positive results, overall worry is low, which may be explained by 
psychological adjustment during the stepwise screening process to the possibility of having 
diabetes. 
Despite low overall worry, those receiving results indicating that they are at risk for or 
currently have diabetes tend to think more about what it would be like to live with diabetes. 
Therefore, an “abnormal” result may increase thought intrusiveness, which could explain higher 
anxiety, distress or worry among those testing positive.  
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Limitations of the Methods  
This review has several limitations. First, due to resources, a dual-review of inclusion, 
data abstraction, and strength of evidence rating was infeasible. Therefore, these results reflect 
one person’s analysis and could change upon review by another analyst.  
Second, only prospective studies were included, which may have limited the 
thoroughness of the analysis. However, even if a cross-sectional study were to show an 
association between screening and a psychological outcome, the very nature of the study design 
would limit the clarity of the causal relationship. In such an event, the next logical step would be 
to examine the association prospectively, as all of the included studies have done. Therefore, the 
likelihood that cross-sectional data would meaningfully change the results is low.  
Finally, I did not include only those studies that examined the overall effect of screening 
by comparing screened vs. unscreened groups. For example, many studies measured outcome 
differences between people diagnosed with screen-detected diabetes and those who underwent 
screening but received a negative result; this comparison approximates only the effect of living 
with the diagnosis of diabetes as a result of screening. In contrast to the former comparison, these 
studies would not provide evidence for the effects of either being invited for screening or waiting 
for the screening test. Nevertheless, the effects of diagnosis and treatment as a result of screening 
are necessary to provide valuable evidence about the entire screening cascade. 
Limitations of the Literature  
The included studies contain some methodological issues that may mask a true difference 
in outcomes between groups, if one exists. For example, all studies had loss to follow-up, some 
to a much higher degree than others; however dropout rates are likely not at random, meaning 
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that the reasons for failing to submit a follow-up questionnaire may be related to the outcome of 
interest.
24,39
  Indeed, prior evidence shows that likelihood of loss to follow-up is associated with 
the degree of anxiety and distress.
40,41
 In other words, those who are more likely to have adverse 
psychological consequences following screening and/or diagnosis, may be less likely to follow-
up with providers, which could differentially affect outcome data. Therefore, the difference 
between groups that drop out may be greater than the difference between groups that remain in 
the study. 
Another limitation is that the studies generally are not able to assess how patients interact 
with their providers regarding diagnosis and treatment.
24
 Because the way in which providers 
frame the potential seriousness of diabetes may affect patients’ attitudes and perceptions, it 
represents an unmeasured determinant of psychological well-being. For example, if providers 
downplay the significance of an “at-risk” screening result, it could mitigate some of the negative 
psychological effects that screening otherwise would have produced. 
The psychological outcomes included in this review can be divided into two major 
categories: general vs. disease-specific. Most of the studies in this review focus on general 
psychological harms such as depression, anxiety and quality of life. Unfortunately, these general 
quality of life measures may miss certain aspects unique to diabetes, which could partially 
explain the apparently small effect that screening has on psychological outcomes.
13
 Indeed, the 
diabetes-specific measures such as worry, intrusiveness and cognitive distress tended to show a 
small but significant association with screening or with a diagnosis of screen-detected diabetes. 
Additionally, past longitudinal research shows that a disease specific outcome, diabetes-related 
distress, occurs more frequently among those with diabetes than does generalized anxiety or 
major depressive disorder.
42
 Therefore, the relative lack of prospective studies that assess 
31 
 
diabetes-specific psychological outcomes means that current evidence may underestimate the 
harms of screening, or at the very least, may paint an incomplete picture of its overall 
psychological effects. 
Implications 
 The overall strength of evidence for the outcomes in this systematic review is low; 
however the results have important implications for practice. The available evidence suggests 
that screening for type 2 diabetes may not be entirely benign; rather it may produce a small 
psychological harm in the form of increased anxiety, distress, worry, or thought intrusiveness. 
Although these harms may appear minimal, it is important to keep in mind that at best, the 
benefits of screening are also small. Therefore, even if the harms seem minor, they can 
meaningfully offset potential benefits such that the net benefit is too small to recommend routine 
screening. Unfortunately, the relative benefits and harms of screening are subject to a large 
degree of uncertainty, as gaps in the evidence still remain. 
Future Research 
 In order to more fully estimate the potential harms of screening for T2DM, future 
research should focus on prospective studies that assess diabetes-related psychological harms. 
For example, studies may focus on diabetes-related distress, measured by validated scales such 
as the Problem Areas in Diabetes (PAID) scale. They may compare screened and unscreened 
individuals, as well as those who screen positive and screen negative to determine the effect of 
screening and diagnosis on diabetes-related distress. Following patients from the pre-screening 
period through diagnosis and treatment of screen-detected diabetes will provide a longitudinal 
account of how patients psychologically handle disease management. Finally, regular assessment 
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of intermediate outcomes such as hemoglobin A1C can offer information about how distress and 
diabetes management influence each other, that is, whether distress determines success of 
management or vice versa.  
Conclusion 
Overall, the available literature is insufficient to say with high certainty that screening for 
T2DM results in meaningful psychological harm, though the included studies hint that screening 
is not entirely benign. This review does provide weak evidence suggesting that screening for 
diabetes is associated with certain psychological harms. The screening process itself produces 
short-term anxiety and worry, whereas the diagnosis of screen-detected diabetes is associated 
with increased cognitive distress and diabetes-related thought intrusion. Treatment, but not 
screening and diagnosis, appears to be associated with elevated depressive symptoms. 
Unfortunately, the available evidence does not cover the entire spectrum of potential 
psychological harms. Only with future research that prospectively investigates more diabetes-
specific psychological harms will we have a more accurate picture of the relative benefits and 
harms of diabetes screening. 
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Embase: 4/3/2013 
1. 'non insulin dependent diabetes mellitus'/exp  
AND  
2. ('screening'/exp OR 'hemoglobin a1c'/exp)  
AND  
3. ('depression'/exp OR 'stress'/exp OR 'distress syndrome'/exp OR 'emotion'/exp OR 
'quality of life'/exp OR 'wellbeing'/exp)  
AND  
4. [humans]/lim  
AND  
5. [embase]/lim  
 
Pubmed 4/5/2013 
1. (diabetes mellitus, type 2 OR "type 2 diabetes" OR "non insulin dependent diabetes" OR 
"impaired fasting glucose" OR "impaired glucose tolerance")  
 
AND  
 
2. (mass screening[MH] OR screen[tw] OR early diagnosis[tw] OR early detection[tw] OR 
"hemoglobin a1c"[tw] OR Hemoglobin A, Glycosylated[MH] OR "fasting glucose" OR 
"glucose tolerance test"[MH])  
 
AND  
 
3. (depression[tw] OR depressed[tw] OR depressive[tw] OR distress[tw] OR stress[tw] OR 
stressed[tw] OR stressful[tw] OR worry[tw] OR worried[tw] OR fear*[tw] OR 
anxiety[tw] OR anxious[tw] OR quality of life[tw] OR mental health[tw] OR mental 
disorders[tw] OR psycholog*[tw] OR well being[tw] OR psychosocial[tw] OR 
uncertainty[tw] OR emotion*[tw]) 
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PsycInfo 4/5/2013:  
1. T1 diabetes mellitus type 2 OR type 2 diabetes 
AND 
2.  ((((((DE "Major Depression") OR (DE "Anxiety")) OR (DE "Stress")) OR (DE 
"Distress")) OR (DE "Quality of Life")) OR (DE "Well Being")) OR (DE "Uncertainty")  
AND 
3. DE "Screening Tests" OR DE "Screening" 
 
Appendix B: Characteristics of Included Studies 
39 
 
Author, Year 
Study Name 
Country Study  
Design 
Patients, 
n 
Comparison 
Groups 
Inclusion 
Criteria 
Outcome Time of 
Assessment 
Rahman et al., 
2012
30
 
 
How much does 
screening bring 
forward the 
diagnosis of type 2 
diabetes and reduce 
complications? 
Twelve year follow-
up of the Ely cohort 
UK Prospective  
Cohort 
 
Total: 152 
 
G1: 92 
 
G2: 60 
G1: People with 
T2DM screened 
in 1990-1992 
 
G2: People with 
T2DM screened 
in 2000-2002 
Adults age 40-
65 living in 
Cambridgeshire 
without 
previously 
diagnosed 
T2DM 
attending a 
single practice 
Mental Health  2002-2003  
(10-12 years 
after G1 
screening;  
1-2 years after 
G2 screening) 
Adriaanse et al., 
2005
25
 
 
Diabetes-related 
symptoms and 
negative mood in 
participants of a 
targeted population-
screening program 
for type 2 diabetes: 
The Hoorn 
Screening Study 
The  
Netherlands 
Prospective  
Cohort 
Total: 319 
 
G1:156 
 
G2:163 
G1: Screen-
detected T2DM 
 
G2: Screen 
negative for 
T2DM 
Adults 50-75 
who were 
"high-risk" (>6 
on Symptom 
Risk 
Questionnaire) 
were invited for 
screening 
1: Psychological 
fatigue 
 
2:Psychological 
cognitive distress 
 
3: Negative mood 
At 2 weeks, 6 
months, and 12 
months after 
diagnosis 
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Author, Year 
Study Name 
Country Study  
Design 
Patients, 
n 
Comparison 
Groups 
Inclusion 
Criteria 
Outcome Time of 
Assessment 
Adriaanse et al., 
2003 
 
Health-related 
quality of life in the 
first year following 
diagnosis of Type 2 
diabetes: newly 
diagnosed patients 
in general practice 
compared with 
screening-detected 
patients. The Hoorn 
Screening Study 
The  
Netherlands 
Prospective  
Cohort 
Total: 165 
 
G1: 49 
 
G2: 116 
G1: Newly 
detected T2DM 
in general 
practice 
 
G2: Screen-
detected T2DM 
Adults 50-75 
who were 
recently 
clinically 
diagnosed with 
T2DM.  
 
Adults 50-75 
"high-risk" (>6 
on Symptom 
Risk 
Questionnaire) 
were invited for 
screening 
1:Psychological 
Fatigue 
 
2: Cognitive Distress 
 
3: Mental Health 
 
4: Negative well-being 
At 2 weeks, 6 
months, and 12 
months after 
diagnosis 
Adriaanse et al., 
2003 
 
No substantial 
psychological 
impact of the 
diagnosis of Type 2 
diabetes following 
targeted population 
screening: The 
Hoorn Screening 
Study 
The  
Netherlands 
Prospective 
Cohort 
Total: 259 
 
G1: 116 
 
G2: 143 
G1: Screen-
detected T2DM 
 
G2: Screen 
negative for 
T2DM 
Adults 50-75 
who were 
"high-risk" (>6 
on Symptom 
Risk 
Questionnaire) 
were invited for 
screening 
1. Negative well-being 
 
2. Mental Health 
At 2 weeks, 6 
months, and 12 
months after 
diagnosis 
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Author, Year 
Study Name 
Country Study  
Design 
Patients, 
n 
Comparison 
Groups 
Inclusion 
Criteria 
Outcome Time of 
Assessment 
Farmer et al., 2003 
 
The impact of 
screening for Type 
2 diabetes in 
siblings of patients 
with established 
diabetes 
UK Prospective 
Cohort 
Total:431 
 
G1: 227 
 
G2: 101 
 
G3: 85 
 
G4: 18 
G1: 
Normoglycemic 
 
G2: Borderline 
 
G3: High Risk 
 
G4: Possible 
Diabetes 
Adults 35-74 
years without 
diabetes who 
have a sibling 
with T2DM 
and were 
identified as 
willing to 
participate by 
sibling 
Primary:  
1. Anxiety 
 
Secondary: 
2. Perceived risk of 
diabetes 
3. Extent to which 
thoughts were 
occupied with 
diabetes/complications 
Primary: 
Before 
screening and 1 
year post-
diagnosis 
Secondary: At 
screening and 1 
year post-
diagnosis 
Rahman et al., 2012 
 
How much does 
screening bring 
forward the 
diagnosis of type 2 
diabetes and reduce 
complications? 
Twelve year follow-
up of the Ely cohort 
UK Prospective 
Cohort 
Total: 
1441 
 
G1: 731 
 
G2: 711 
G1: People 
screened 
negative for 
T2DM  in 1990-
1992 
 
G2: People 
screened 
negative for 
T2DM  in 2000-
2003 
Adults age 40-
65 living in 
Cambridgeshire 
without 
previously 
diagnosed 
T2DM who 
attend a single 
practice 
Mental Health  2002-2003  
(10-13 years 
after G1 
screening;  
1-3 years after 
G2 screening) 
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Author, Year 
Study Name 
Country Study  
Design 
Patients, 
n 
Comparison 
Groups 
Inclusion 
Criteria 
Outcome Time of 
Assessment 
Paddison et al., 
2011 
 
Predictors of 
anxiety and 
depression among 
people attending 
diabetes 
screening:A 
propspective cohort 
study embedded in 
the ADDITION 
(Cambridge) 
randomized 
controlled trial 
UK Prospective 
Cohort 
Total: 
3240 
G1: Screen-
detected T2DM 
 
G2: Screen 
negative for 
T2DM 
Adults 40-69 
years in top 
quartile of 
Cambridge 
Diabetes Risk 
Score were 
invited to 
screening 
1.Anxiety 
 
2.Depression 
Following 
known results 
of RBG and at 
12 months 
follow-up 
Paddison et al., 
2009 
 
Are people with 
negative diabetes 
screening tests 
falsely reassured? 
Parallel group 
cohort study 
embedded in the 
ADDITION 
(Cambridge) 
randomised 
controlled trial 
UK Prospective 
Cohort 
Total: 
5334 
 
G1:964 
 
G2: 4370 
G1: Unscreened 
 
G2: Screened 
negative for 
T2DM 
Adults 40-69 
years in top 
quartile of 
Cambridge 
Diabetes Risk 
Score were 
invited to 
screening or 
questionnaire 
without 
screening 
False reassurance 
 
1. Personal Risk 
 
2. Comparative Risk 
 After initial 
screening test, 
at 3-6 months, 
then 12-15 
months after 
screening 
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Author, Year 
Study Name 
Country Study  
Design 
Patients, 
n 
Comparison 
Groups 
Inclusion 
Criteria 
Outcome Time of 
Assessment 
Golden et al., 2008 
 
Examining a 
Bidirectional 
Association 
Between Depressive 
Symptoms and 
Diabetes 
(Multi-Ethnic Study 
of Atherosclerosis) 
US Prospective 
Cohort 
Total: 
4847 
 
G1: 2868 
 
G2: 1357 
 
G3: 203 
 
G4: 417 
G1: Screen 
negative for 
T2DM 
G2: Screened 
Impaired Fasting 
Glucose 
G3: Screened 
positive for 
T2DM-untreated 
G4: Screened 
positive for 
T2DM-treated 
Men and 
women 45-84 
white, black, 
Hispanic, 
Chinese 
without self-
reported 
cardiovascular 
disease without 
baseline 
depressive 
symptoms or 
antidepressant 
medication use 
Depressive symptoms 5 year follow-
up 
Edelman et al., 
2002 
 
Impact of Diabetes 
Screening on 
Quality of Life 
US Prospective 
Cohort 
Total:1253 
 
G1:1177 
 
G2: 56 
G1: Screened-
negative for 
T2DM 
G2: Screened-
positive for 
T2DM 
Men and 
women 45-64 
at outpatient 
DVAMC 
without 
diabetes at 
baseline 
Mental Health  Baseline and 1 
year after 
enrollment 
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Author, Year 
Study Name 
Country Study  
Design 
Patients, 
n 
Comparison 
Groups 
Inclusion 
Criteria 
Outcome Time of 
Assessment 
Icks et al, 2013 
 
Risk for High 
Depressive 
Symptoms in 
Diagnosed and 
Previously 
Undetected 
Diabetes: 5-year 
follow-up results of 
the Heinz Nixdorf 
Recall Study 
Germany Prospective 
Cohort 
Total 3633 G1: Previously 
Diagnosed 
T2DM 
 
G2: Screen-
detected T2DM 
 
G3: Screen-
negative for 
T2DM 
Men and 
women 45-75 
without 
depressive 
symptoms at 
baseline 
Depressive symptoms At 5 years 
Park et al., 2008 
 
Screening for type 2 
diabetes is feasible, 
acceptable, but 
associated with 
increased short-term 
anxiety: A 
randomized 
controlled trial in 
British general 
practice 
UK Randomized 
Controlled 
Trial 
Total: 355 
 
G1: 238 
 
G2: 116 
Individual-
randomization 
 
G1: Unscreened 
 
G2: Screened  
Adults 40-69 
without known 
diabetes, 
identified as 
high risk using 
a risk score 
1. Anxiety 6 weeks post 
screening or 
invitation 
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Author, Year 
Study Name 
Country Study  
Design 
Patients, 
n 
Comparison 
Groups 
Inclusion 
Criteria 
Outcome Time of 
Assessment 
Eborall et al., 2008 
 
Psychological 
impact of screening 
for type 2 diabetes: 
controlled trial and 
comparative study 
embedded in the 
ADDITION 
(Cambridge) 
randomised trial 
UK Non-
randomized 
controlled 
trial 
Total: 
7380 
 
G1: 6416 
 
G2: 964 
G1: Screened 
 
G2: Unscreened 
Adults 40-69 in 
the top fourth 
for risk of 
haivng 
undiagnosed 
type 2 diabetes 
1.State Anxiety 
 
2. Anxiety 
 
3. Depression 
 
4. Worry 
At RBG, 3-6 
months, and 
12-15 months 
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Author, Year 
Study Name 
Was 
randomization 
adequate? 
 
Was 
allocation 
concealment 
adequate? 
Were groups 
similar at 
baseline? 
Were 
outcome 
assessors/ 
providers/ 
patients 
masked? 
Was 
overall 
attrition 
≥20%?  
Was 
differential 
attrition 
≥15%? 
Did the 
study use 
ITT 
analyses?  
Proper 
analysis? 
(adjustment 
for 
confounders) 
Were 
outcome 
measures 
equal, valid 
and reliable? 
Overall 
Internal 
Validity 
Rahman et al., 
2012 
 
How much 
does screening 
bring forward 
the diagnosis 
of type 2 
diabetes and 
reduce 
complications? 
Twelve year 
follow-up of 
the Ely cohort 
N/A-Cohort 
Study 
 
N/A-Cohort 
Study 
No: Recently 
screened 
group had 
more people 
on antiplatelet 
drugs, had 
higher 
retinopathy 
rates, and had 
more people 
with ECG 
confirmed 
ischemic 
heart disease 
compared to 
screened in 
the past 
Yes/No/No Yes No N/A-
Cohort 
Study 
No-did not 
adjust for 
baseline 
differences, did 
not adjust for 
multiple testing 
Yes Fair 
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Author, Year 
Study Name 
Was 
randomization 
adequate? 
 
Was 
allocation 
concealment 
adequate? 
Were groups 
similar at 
baseline? 
Were 
outcome 
assessors/ 
providers/ 
patients 
masked? 
Was 
overall 
attrition 
≥20%?  
Was 
differential 
attrition 
≥15%? 
Did the 
study use 
ITT 
analyses?  
Proper 
analysis? 
(adjustment 
for 
confounders) 
Were 
outcome 
measures 
equal, valid 
and reliable? 
Overall 
Internal 
Validity 
Adriaanse et 
al., 2005 
 
Diabetes-
related 
symptoms and 
negative mood 
in participants 
of a targeted 
population-
screening 
program for 
type 2 
diabetes: The 
Hoorn 
Screening 
Study 
N/A-Cohort 
Study 
 
N/A-Cohort 
Study 
No: Screen 
positive group 
had higher 
blood glucose 
and slightly 
higher 
symptom risk 
score 
N/A-Self-
reported 
questionnaire 
by mail/ 
 No /No 
Yes No N/A-
Cohort 
Study 
No-did not 
adjust for 
baseline 
differences, did 
not account for 
multiple testing 
Yes Fair 
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Author, Year 
Study Name 
Was 
randomization 
adequate? 
 
Was 
allocation 
concealment 
adequate? 
Were groups 
similar at 
baseline? 
Were 
outcome 
assessors/ 
providers/ 
patients 
masked? 
Was 
overall 
attrition 
≥20%?  
Was 
differential 
attrition 
≥15%? 
Did the 
study use 
ITT 
analyses?  
Proper 
analysis? 
(adjustment 
for 
confounders) 
Were 
outcome 
measures 
equal, valid 
and reliable? 
Overall 
Internal 
Validity 
Adriaanse et 
al., 2003 
 
Health-related 
quality of life 
in the first 
year following 
diagnosis of 
Type 2 
diabetes: 
newly 
diagnosed 
patients in 
general 
practice 
compared with 
screening-
detected 
patients. The 
Hoorn 
Screening 
Study 
N/A-Cohort 
Study 
 
N/A-Cohort 
Study 
No: Screen-
detected 
group had 
lower A1c, 
were more 
overweight, 
were more 
likely 
hypertensive, 
much less 
likely to be on 
blood glucose 
lowering 
medications, 
N/A-Self-
reported 
questionnaire 
by mail / 
No /No 
Yes No N/A-
Cohort 
Study 
No-Did not 
adjust for 
baseline 
differences, did 
not account for 
multiple 
testing, which 
would have  
made 
everything 
non-significant 
Yes Fair 
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Author, Year 
Study Name 
Was 
randomization 
adequate? 
 
Was 
allocation 
concealment 
adequate? 
Were groups 
similar at 
baseline? 
Were 
outcome 
assessors/ 
providers/ 
patients 
masked? 
Was 
overall 
attrition 
≥20%?  
Was 
differential 
attrition 
≥15%? 
Did the 
study use 
ITT 
analyses?  
Proper 
analysis? 
(adjustment 
for 
confounders) 
Were 
outcome 
measures 
equal, valid 
and reliable? 
Overall 
Internal 
Validity 
Adriaanse et 
al., 2003 
 
No substantial 
psychological 
impact of the 
diagnosis of 
Type 2 
diabetes 
following 
targeted 
population 
screening: The 
Hoorn 
Screening 
Study 
N/A-Cohort 
Study 
 
N/A-Cohort 
Study 
No-diabetes 
group had 
higher 
glucose 
levels, greater 
degree of 
dyspnea on 
exertion and 
less likely to 
use bicycle 
for 
transportation 
N/A-Self-
reported 
questionnaire 
by mail/  
No/ No 
No No N/A-
Cohort 
Study 
No-only 
adjusted for 
baseline 
scores. Did not 
adjust for other 
baseline 
imbalances and 
did not account 
for multiple 
testing 
Yes Fair 
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Author, Year 
Study Name 
Was 
randomization 
adequate? 
 
Was 
allocation 
concealment 
adequate? 
Were groups 
similar at 
baseline? 
Were 
outcome 
assessors/ 
providers/ 
patients 
masked? 
Was 
overall 
attrition 
≥20%?  
Was 
differential 
attrition 
≥15%? 
Did the 
study use 
ITT 
analyses?  
Proper 
analysis? 
(adjustment 
for 
confounders) 
Were 
outcome 
measures 
equal, valid 
and reliable? 
Overall 
Internal 
Validity 
Farmer et al., 
2003 
 
The impact of 
screening for 
Type 2 
diabetes in 
siblings of 
patients with 
established 
diabetes 
N/A-Cohort 
Study 
 
N/A-Cohort 
Study 
No- Those 
with diabetes 
were more 
likely male, 
had higher 
BMI; other 
characteristics 
unclear due to 
reporting 
N/A-Self-
reported 
questionnaire 
by mail/  
No/ No 
No  No N/A-
Cohort 
Study 
No-did not 
adjust for past 
treatment of 
depression or 
any other 
potential 
confounders in 
list of baseline 
characteristics 
Yes Fair 
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Author, Year 
Study Name 
Was 
randomization 
adequate? 
 
Was 
allocation 
concealment 
adequate? 
Were groups 
similar at 
baseline? 
Were 
outcome 
assessors/ 
providers/ 
patients 
masked? 
Was 
overall 
attrition 
≥20%?  
Was 
differential 
attrition 
≥15%? 
Did the 
study use 
ITT 
analyses?  
Proper 
analysis? 
(adjustment 
for 
confounders) 
Were 
outcome 
measures 
equal, valid 
and reliable? 
Overall 
Internal 
Validity 
Rahman et al.,  
2012 
How much 
does screening 
bring forward 
the diagnosis 
of type 2 
diabetes and 
reduce 
complications? 
Twelve year 
follow-up of 
the Ely cohort 
N/A-Cohort 
Study 
 
N/A-Cohort 
Study 
Yes Yes/No/No Yes (54 
vs 46) 
No N/A-
Cohort 
Study 
No-there was 
no adjustment: 
the data were 
exploratory, 
but did not 
account for 
multiple testing 
Yes Fair: 
high 
attrition 
rate 
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Author, Year 
Study Name 
Was 
randomization 
adequate? 
 
Was 
allocation 
concealment 
adequate? 
Were groups 
similar at 
baseline? 
Were 
outcome 
assessors/ 
providers/ 
patients 
masked? 
Was 
overall 
attrition 
≥20%?  
Was 
differential 
attrition 
≥15%? 
Did the 
study use 
ITT 
analyses?  
Proper 
analysis? 
(adjustment 
for 
confounders) 
Were 
outcome 
measures 
equal, valid 
and reliable? 
Overall 
Internal 
Validity 
Paddison et 
al., 2011 
 
Predictors of 
anxiety and 
depression 
among people 
attending 
diabetes 
screening:A 
propspective 
cohort study 
embedded in 
the 
ADDITION 
(Cambridge) 
RCT 
N/A-Cohort 
Study 
 
 
N/A-Cohort 
Study 
Unclear/Not-
reported 
Unclear / 
No/No 
Yes Unclear/not-
reported 
N/A-
Cohort 
Study 
Yes in logistic 
regression, but 
not in chi 
square analysis 
of prevalence 
of depressive 
symptoms. Did 
not address 
multiple 
comparisons 
Yes Fair: 
high 
attrition 
rate 
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Author, Year 
Study Name 
Was 
randomization 
adequate? 
 
Was 
allocation 
concealment 
adequate? 
Were groups 
similar at 
baseline? 
Were 
outcome 
assessors/ 
providers/ 
patients 
masked? 
Was 
overall 
attrition 
≥20%?  
Was 
differential 
attrition 
≥15%? 
Did the 
study use 
ITT 
analyses?  
Proper 
analysis? 
(adjustment 
for 
confounders) 
Were 
outcome 
measures 
equal, valid 
and reliable? 
Overall 
Internal 
Validity 
Paddison et 
al., 2009 
 
Are people 
with negative 
diabetes 
screening tests 
falsely 
reassured? 
Parallel group 
cohort study 
embedded in 
the 
ADDITION 
(Cambridge) 
randomised 
controlled trial 
N/A-Cohort 
Study 
 
N/A-Cohort 
Study 
Yes Unclear / 
No/No 
Yes Yes N/A-
Cohort 
Study 
Yes-No 
measured 
confounders, 
but did not 
measure 
educational 
status (could 
be associated 
with 
understanding). 
Did not 
address 
missing data or 
multiple 
testing. 
Measures 
were 
equal.Unclear 
as to validity 
and reliability 
Fair 
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Author, Year 
Study Name 
Was 
randomization 
adequate? 
 
Was 
allocation 
concealment 
adequate? 
Were groups 
similar at 
baseline? 
Were 
outcome 
assessors/ 
providers/ 
patients 
masked? 
Was 
overall 
attrition 
≥20%?  
Was 
differential 
attrition 
≥15%? 
Did the 
study use 
ITT 
analyses?  
Proper 
analysis? 
(adjustment 
for 
confounders) 
Were 
outcome 
measures 
equal, valid 
and reliable? 
Overall 
Internal 
Validity 
Golden et al., 
2008 
 
Examining a 
Bidirectional 
Association 
Between 
Depressive 
Symptoms and 
Diabetes 
N/A-Cohort 
Study 
 
N/A-Cohort 
Study 
No- Those 
with diabetes 
were more 
likely male, 
african 
american, 
were less 
educated, had 
lower income, 
and had 
higher rates 
of 
hypertension 
Unclear/ 
No/No 
No  Unclear/not-
reported 
N/A-
Cohort 
Study 
Yes-Although 
did not address 
missing data 
Yes Fair to 
good 
Edelman et al., 
2002 
Impact of 
Diabetes 
Screening on 
Quality of Life 
N/A-Cohort 
Study 
 
N/A-Cohort 
Study 
Unclear/Not-
reported 
Unclear / 
No/No 
No  No N/A-
Cohort 
Study 
Yes-Although 
did not report 
baseline 
covariates, they 
used 
ANCOVA for 
measured 
baseline scores 
Yes Fair 
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Author, Year 
Study Name 
Was 
randomization 
adequate? 
 
Was 
allocation 
concealment 
adequate? 
Were groups 
similar at 
baseline? 
Were 
outcome 
assessors/ 
providers/ 
patients 
masked? 
Was 
overall 
attrition 
≥20%?  
Was 
differential 
attrition 
≥15%? 
Did the 
study use 
ITT 
analyses?  
Proper 
analysis? 
(adjustment 
for 
confounders) 
Were 
outcome 
measures 
equal, valid 
and reliable? 
Overall 
Internal 
Validity 
Icks et al., 
2013 
 
Risk for High 
Depressive 
Symptoms in 
Diagnosed and 
Previously 
Undetected 
Diabetes: 5-
year follow-up 
results of the 
Heinz Nixdorf 
Recall Study 
N/A-Cohort 
Study 
 
 
N/A-Cohort 
Study 
No-No 
diabetes 
group had 
more women, 
more 
exercise, 
lower BMI 
Unclear/ 
Unclear/ 
No 
No  No N/A-
Cohort 
Study 
Yes, multiple 
logistic 
regression 
models 
adjusted for 
measured 
baseline 
differences; 
however did 
not measure 
steroid use 
Yes Fair to 
good 
Park et al., 
2008 
 
Screening for 
type 2 diabetes 
is feasible, 
acceptable, but 
associated 
with increased 
short-term 
anxiety: A 
RCT in British 
general 
practice 
Unclear/not 
reported: did 
not discuss 
randomization 
protocol 
 
Unclear: likely 
was given 
computerized 
randomization 
Yes Unclear/ 
No/No 
Yes No No-
analyzed 
completers 
only 
Yes-No 
baseline 
indifferences, 
but did not 
assess baseline 
anxiety 
Yes Fair 
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Author, Year 
Study Name 
Was 
randomization 
adequate? 
 
Was 
allocation 
concealment 
adequate? 
Were groups 
similar at 
baseline? 
Were 
outcome 
assessors/ 
providers/ 
patients 
masked? 
Was 
overall 
attrition 
≥20%?  
Was 
differential 
attrition 
≥15%? 
Did the 
study use 
ITT 
analyses?  
Proper 
analysis? 
(adjustment 
for 
confounders) 
Were 
outcome 
measures 
equal, valid 
and reliable? 
Overall 
Internal 
Validity 
Eborall et al., 
2008 
 
Psychological 
impact of 
screening for 
type 2 
diabetes: 
controlled trial 
and 
comparative 
study 
embedded in 
the 
ADDITION 
(Cambridge) 
randomised 
trial 
N/A-Initially 
randomized at 
practice level, 
but this 
substudy was 
not randomized 
in which 
clinics they 
used 
 
No-
investigators 
knew which 
practices were 
coming from 
initial study 
group  
Yes Unclear/ 
No/No 
Yes Yes No-
analyzed 
completers 
only 
Yes, though 
did not adjust 
for multiple 
comparisons 
Yes Fair 
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Author, Year 
Study Name 
Population 
(G/F/P) 
Situation 
(G/F/P) 
Providers 
(G/F/P) 
Overall External 
Validity 
Rahman et al., 2012 
How much does screening 
bring forward the diagnosis of 
type 2 diabetes and reduce 
complications? Twelve year 
follow-up of the Ely cohort 
Fair-All of the people in the 
study had diagnosed diabetes; 
people with screen negative 
for diabetes were excluded;   
almost all caucasian 
Good Good Fair 
Adriaanse et al., 2005 
Diabetes-related symptoms 
and negative mood in 
participants of a targeted 
population-screening program 
for type 2 diabetes: The Hoorn 
Screening Study 
Fair: Almost all caucasian, 
were identified through 
symptom questionnaire: may 
be unlike an asymptomatic 
screening group 
Fair: step-wise screening 
process 
Good Fair 
Adriaanse et al., 2003 
Health-related quality of life in 
the first year following 
diagnosis of Type 2 diabetes: 
newly diagnosed patients in 
general practice compared 
with screening-detected 
patients. The Hoorn Screening 
Study 
Fair: Almost all caucasian, 
were identified through 
symptom questionnaire: may 
be unlike an asymptomatic 
screening group 
Fair: step-wise screening 
process 
Good Fair 
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Author, Year 
Study Name 
Population 
(G/F/P) 
Situation 
(G/F/P) 
Providers 
(G/F/P) 
Overall External 
Validity 
Adriaanse et al., 2003 
No substantial psychological 
impact of the diagnosis of 
Type 2 diabetes following 
targeted population screening: 
The Hoorn Screening Study 
Fair: Almost all caucasian, 
were identified through 
symptom questionnaire: may 
be unlike an asymptomatic 
screening group 
Fair-Stepwise screening 
approach 
Good Fair 
Farmer et al., 2003 
The impact of screening for 
Type 2 diabetes in siblings of 
patients with established 
diabetes 
Fair-People belonged to big 
families, and were primarily 
caucasian 
Fair-People likely not 
used to being 
approached for 
screening on account of 
a family member 
screening positive 
Good Fair 
Rahman et al., 2012 
How much does screening 
bring forward the diagnosis of 
type 2 diabetes and reduce 
complications? Twelve year 
follow-up of the Ely cohort 
Poor-None of the people in 
the study had diagnosed 
diabetes; they were excluded 
from the analysis; people 
were generally healthy and 
almost all caucasian 
Good Good Fair 
Paddison et al., 2011 
Predictors of anxiety and 
depression among people 
attending diabetes screening:A 
propspective cohort study 
embedded in the ADDITION 
(Cambridge) randomized 
controlled trial 
Fair: Patients were at "highest 
risk" for T2DM, likely higher 
than average screened person 
in U.S.; Affluent patients 
Fair to poor: had step-
wise screening process 
Good Fair 
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Author, Year 
Study Name 
Population 
(G/F/P) 
Situation 
(G/F/P) 
Providers 
(G/F/P) 
Overall External 
Validity 
Paddison et al., 2009 
Are people with negative 
diabetes screening tests falsely 
reassured? Parallel group 
cohort study embedded in the 
ADDITION (Cambridge) 
randomised controlled trial 
Fair: Patients were at "highest 
risk" for T2DM, likely higher 
than average screened person 
in U.S.; Affluent patients 
Fair to poor: had step-
wise screening process 
Good Fair 
Golden et al., 2008 
Examining a Bidirectional 
Association Between 
Depressive Symptoms and 
Diabetes 
Good Good Good  Good 
Edelman et al., 2002 
Impact of Diabetes Screening 
on Quality of Life 
Good Good Good Good 
Icks et al, 2013 Good Fair: low percentage of 
screen-detected T2DM 
untreated 
Good Fair 
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Author, Year 
Study Name 
Population 
(G/F/P) 
Situation 
(G/F/P) 
Providers 
(G/F/P) 
Overall External 
Validity 
Park et al., 2008 
Screening for type 2 diabetes 
is feasible, acceptable, but 
associated with increased 
short-term anxiety: A 
randomized controlled trial in 
British general practice 
Fair: Patients were at "highest 
risk" for T2DM, likely higher 
than average screened person 
in U.S.; Affluent patients 
Fair: step-wise screening 
process 
Good Fair 
Eborall et al., 2008 
Psychological impact of 
screening for type 2 diabetes: 
controlled trial and 
comparative study embedded 
in the ADDITION 
(Cambridge) randomised trial 
Fair: Patients were at "highest 
risk" for T2DM, likely higher 
than average screened person 
in U.S. 
Fair to poor: had step-
wise screening process 
Good Fair 
 
